Electrocardiography

Fujitsu and University of Tokyo Hospital Embark on Joint Research into AI to Aid the Fight Against Heart Disease

Monday, October 11, 2021 - 2:29am

Since December 2019, Fujitsu has been making progress with research and development of proprietary AI technology(2) in collaboration with the University of Tokyo Hospital.

Key Points: 
  • Since December 2019, Fujitsu has been making progress with research and development of proprietary AI technology(2) in collaboration with the University of Tokyo Hospital.
  • The AI will be used in clinical field research to estimate the presence or absence of abnormal heart movements based on the data of patients undergoing electrocardiographic procedures at the University of Tokyo Hospital.
  • Based on the electrocardiogram data of patients examined at the University of Tokyo Hospital, Fujitsu and the University of Tokyo Hospital will verify the effectiveness of detection of abnormal heart movement by AI.
  • Through its joint research with the University of Tokyo Hospital, Fujitsu will continue to actively promote research and development of AI to detect various heart diseases.

eyeson 'layouts' enable adding participants and data sources most flexibly to video meetings

Friday, September 10, 2021 - 1:09pm

The eyeson API enables seamless integration of live video into digital workflows with full customization options and managed servers.

Key Points: 
  • The eyeson API enables seamless integration of live video into digital workflows with full customization options and managed servers.
  • With the eyeson API, developers can integrate various types of data sources, media streams or pictures and documents as a custom video stream.
  • eyeson provides an API video service to easily integrate live video, including live media, data and participants, into any kind of use-case based on its unique patented single-stream technology.
  • To secure customers' performance, eyeson offers the service to manage cloud capacity, scalable video coding performance and data management.

The Worldwide Wireless Electrocardiography Device Industry is Expected to Reach $2.2+ Billion by 2027 - ResearchAndMarkets.com

Monday, September 6, 2021 - 9:21am

Wireless Electrocardiography (ECG) Devices Market Analysis, By Type

Key Points: 
  • Wireless Electrocardiography (ECG) Devices Market Analysis, By Type
    Chapter 6.
  • Wireless Electrocardiography (ECG) Devices Market Analysis, By Modality
    Chapter 8.
  • Wireless Electrocardiography (ECG) Devices Market Analysis, By End User
    Chapter 9.
  • Wireless Electrocardiography (ECG) Devices Market Analysis, By Country
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210906005054/en/

Medical Electrodes Markets: Electrocardiography, Electroencephalography & Brainstem Auditory Evoked Potential, Electromyography - Global Industry Analysis and Demand Forecast to 2025 - ResearchAndMarkets.com

Thursday, August 26, 2021 - 3:59pm

The "Medical Electrodes Market Research Report - Global Industry Analysis and Demand Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Electrodes Market Research Report - Global Industry Analysis and Demand Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
  • Global medical electrodes market is predicted to grow at a 6.7% CAGR between 2021 and 2025, to reach $1,151.6 million by 2025.
  • Rising volume of minimally invasive procedures, booming geriatric population, and increasing prevalence of lifestyle-associated and chronic diseases, the usage of medical electrodes is surging.
  • To be more profitable, players in the medical electrodes market are constantly launching new and improved products.

EchoNous Partners with Us2.ai for Machine Learning-enabled Analysis of Heart Scans

Thursday, August 5, 2021 - 5:00pm

Us2.ais software is being integrated into EchoNouss Kosmos Platform, enabling automated analysis of heart structures that are scanned with Kosmos; saving work flow time and improving accuracy.

Key Points: 
  • Us2.ais software is being integrated into EchoNouss Kosmos Platform, enabling automated analysis of heart structures that are scanned with Kosmos; saving work flow time and improving accuracy.
  • The Us2.ai partnership with EchoNous is exclusive Kosmos will be the only device in its size category to carry the software.
  • By integrating our software into EchoNous devices, were combining our AI-driven analysis with Kosmos superior imaging quality and mobility.
  • Its flagship device, Kosmos, offers diagnostic-quality heart, lung, and abdominal scans in a handheld tool.

Study Reveals Video Emails Offer Relief as Inbox Fatigue Continues to Rise

Wednesday, August 4, 2021 - 2:00pm

Some participants also remembered video content better than text and may be far more likely to act on a video message than a text message -- an essential finding for employers and leaders of sales organizations looking for new ways to engage customers.

Key Points: 
  • When shown a video message, respondents tended to enter a happy, pleased, or alert state and feel less fatigue.
  • In addition, viewers who read text with embedded video felt fewer negative emotions than those who read text alone.
  • Videos that included dynamic effects (e.g., animation, motion, sound effects, screenshots) and relevant video titles have an even higher chance of memorability.
  • Participants tended to feel more motivated and less fatigued while viewing the video emails versus text emails.

MindMics Announces Results from a Clinical Trial of Revolutionary Earbuds Technology -- In-ear Infrasonic Hemodynography - to Achieve Cardiac Arrhythmia Assessment beyond that of ECG

Monday, August 2, 2021 - 12:12pm

CAMBRIDGE, Mass., Aug. 2, 2021 /PRNewswire/ - MindMics, Inc. reported results from the clinical trial of revolutionary earbuds that make use of a new technology -- in-ear infrasonic hemodynography (IH) - for the monitoring of cardiac arrhythmias, resulting in insights beyond those that have been possible with state-of-the-art ECG monitoring. These results were presented at the Heart Rhythm Society meeting in Boston, July 30, 2021.

Key Points: 
  • The clinical trial for recruiting atrial fibrillation (AF) patients was approved by the institutional review board of The University of South Carolina School of Medicine.
  • Synchronized MindMics In-ear Infrasonic Hemodynography (IH) data and ECG were simultaneously recorded from 15 patients in AF and 15 in SR for 20 minutes.
  • Recruited AF patients were between the ages of 45 years and 90 years and showed a variety of arrhythmias.
  • An oral presentation titled "MindMics: In-ear Infrasonic Hemodynography For Cardiac Arrhythmia Assessment Beyond ECG"was given at the Heart Rhythm Society 2021 Annual Meeting: Bringing the World of EP (Electrophysiology) Together on July 28-31.

BIOTRONIK Applauded by Frost & Sullivan for Its Disruptive Implantable Cardiac Monitoring Device, BIOMONITOR IIIm

Wednesday, July 28, 2021 - 11:00am

LONDON, July 28, 2021 /PRNewswire/ -- Based on its recent analysis of the Global market for implantable cardiac monitoring devices, Frost & Sullivan recognizes BIOTRONIK with the 2021 Global Enabling Technology Leadership Award. The company's subcutaneous miniature, injectable electrocardiogram (ECG) device, BIOMONITOR IIIm, enhances patient outcomes with its highly accurate ECG, temperature, and activity measurement. The device's unique BIOvector design optimizes the signal quality to generate high-definition ECGs and ensure maximum precision in the recorded rhythm disturbance.

Key Points: 
  • The company's subcutaneous miniature, injectable electrocardiogram (ECG) device, BIOMONITOR IIIm, enhances patient outcomes with its highly accurate ECG, temperature, and activity measurement.
  • "Used with the BIOTRONIK Home Monitoring solution, it enables patients' recorded cardiac rhythm disturbance to be automatically and wirelessly transmitted to physicians.
  • Frost & Sullivan believes that BIOMONITOR IIIm, with the high precision and industry-leading battery life, will disrupt the implantable cardiac home monitoring market."
  • The innovative algorithm adapts to each patient's unique heart rhythm, resulting in higher accuracy than competing implantable cardiac monitoring devices.

New Study Demonstrates KardiaMobile 6L Reduces Urgent Healthcare Utilization

Tuesday, July 27, 2021 - 10:59pm

The KardiaMobile 6L device was developed and is manufactured by AliveCor , an innovative leader in FDA-cleared personal electrocardiogram (ECG) technology and services.

Key Points: 
  • The KardiaMobile 6L device was developed and is manufactured by AliveCor , an innovative leader in FDA-cleared personal electrocardiogram (ECG) technology and services.
  • "The data from our study showed that remote patient ECG monitoring reassured patients and reduced patient and provider exposure by decreasing healthcare utilization overall."
  • In the poster titled "Reduction In Urgent Healthcare Visits By Using A Mobile Electrocardiographic Device (Board #B-PO03-184)," investigators compared the healthcare utilization of 128 KardiaMobile ECG users for one year prior to obtaining the device and one year after.
  • "We are encouraged by the results of the first-ever study demonstrating use of our technology and services reduces healthcare utilization," said David Albert, MD, Chief Medical Officer, AliveCor.

Insights on the Single Lead ECG Equipment Global Market to 2027 - Featuring AliveCor, Contec Medical Systems and Eurocamina Among Others - ResearchAndMarkets.com

Friday, July 23, 2021 - 11:56am

The "Single Lead ECG Equipment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Single Lead ECG Equipment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Syncope, one of the segments analyzed in the report, is projected to record a 4.3% CAGR and reach US$216.7 Million by the end of the analysis period.
  • The U.S. Market is Estimated at $100.6 Million, While China is Forecast to Grow at 7.3% CAGR
    The Single Lead ECG Equipment market in the U.S. is estimated at US$100.6 Million in the year 2020.
  • In the global Other Indications segment, USA, Canada, Japan, China and Europe will drive the 4% CAGR estimated for this segment.